Growing Prevalence of ENT Disorders Triggered by Environmental Factors to Bolster Demand for Treatments

Published Date : May 29, 2017

Albany, New York, May 29, has announced the addition of a report, titled “Global ENT Disorder Treatment Market 2017-2021” to its offering. The comprehensive report on the global ENT disorder treatment provides insight into the current market status, notable trends, share and size of key segments, drug classes, and competitive landscape. The research study highlights the recent technological advances in therapeutics and evaluates their impact on emerging opportunities in major regions. The study assesses key factors affecting major conditions influencing the incidence of ENT (ear, nose, and throat) disorders across various regions. Emerging treatment modalities of key ENT disorders in major regions such as the Americas, Europe, and the EMEA are elaborated in the study.

The global market for ENT disorder treatment is projected to grow at a CAGR of 2.17% from 2017 to 2021. Treatments for ENT have gained significance over the past few decades owing to the external environmental factors affecting the functioning of eyes, ear, and nose. The market is driven by increasing number of people suffering from ENT disorders leading to conditions such as vision loss, hearing impairment, and chronic throat infections.

The soaring pollution level, especially in urban places, has mainly led to the incidence of sinus problems among populations, among other disorders. The number of people suffering with reoccurring sinusitis involving the inflammation in the nasal passages for long duration has been growing in developed regions such as North America. This has propelled the demand for ENT disorder treatments. Other common conditions associated with ENT that need treatment are inflamed mucous membranes, sore throats, tonsillitis, ear aches, and loss of balance. Furthermore, the growing number of children with special ENT disorders is expected to catalyze the market growth in the coming years. 

For Sample Copy, click here: 

The growing prevalence of perennial allergic rhinitis has led many people to seek clinical help, thereby boosting the ENT disorder treatment market. The indiscriminate and superfluous intake of antibiotics has further worsened the situation since this has resulted in pathogens to become antibiotic resistant. New treatment modalities have emerged for treating chronic conditions of ENT disorders. For instance research are ongoing to find powerful treatments for allergic rhinitis. Such developments augur well for the ENT disorder treatment market.

The growing prominence of benign or cancerous tumors affecting vision and hearing has been growing. This has led to the demand for reconstructive procedures done by ENT specialists. Constant advances in therapeutics have led to a better understanding of bacteria, viruses, and pathogens causing ENT disorders. This is expected to fuel the ENT disorder treatment market. 

Leading companies operating in the ENT disorder treatment market include Sanofi S.A., Novartis, and GlaxoSmithKline. Some of the prominent vendors in the market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer, Otonomy Inc., Merck & Co., Dr. Reddy's Laboratories, AstraZeneca, and Allergan. 

To order report Call Toll Free: 866-997-4948 or send an email on